As AI becomes a rising force in healthcare, biomedical companies are racing to carve out a share of the growing market. Crystalvue Medical and Medimaging Integrated Solution are focusing on AI-powered products related to the five senses, while Ever Fortune.AI, aetherAI, and AmCad BioMed are targeting diagnostic applications. Meanwhile, iXensor and BONRAYBIO have set their sights on the fertility market.
Johnsee Lee, Honorary Chairman of the Taiwan Bio Industry Organization, stated that AI’s greatest value lies in new drug development. In the future, using AI to screen drug candidates and design clinical trials will be key to increasing the success rate of drug development, shortening time-to-market, and reducing costs. While domestic companies are currently more focused on diagnostics and image analysis, their strengths in semiconductors and AI technologies are expected to give them a competitive edge.
Preliminary statistics show that many AI-driven products in diagnostics, monitoring, and smart healthcare have already been commercialized and successfully entered international markets.
In the field of ophthalmic diagnostics, Medimaging Integrated Solution has developed AI-powered retinal image analysis software to detect ocular diseases. With product lines such as disposable cystoscopes and otoscopes, the company’s revenue grew nearly 30% year-on-year in the first four months, turning a profit in Q1. Crystalvue Medical, which offers fundus cameras and AI-assisted diagnostic solutions for retinal imaging, has established collaborations with multiple AI companies. Acer Medical, focused on integrating AI into healthcare, launched Taiwan’s first AI-powered ophthalmology software to receive market approval in 2020.
In the smart healthcare segment, Onyx Healthcare has developed a range of AI medical products, including image analysis tools, medical computing systems, and mobile nursing solutions, which have been adopted by international healthcare providers. The share of revenue from AI-powered medical devices continues to grow. aetherAI specializes in digital pathology solutions and AI-assisted medical image diagnostics, currently offering over ten AI diagnostic tools.
Ever Fortune.AI is engaged in developing AI-assisted diagnostic tools across multiple medical specialties, and has obtained over 40 regulatory approvals domestically and internationally, including for bone age assessment and ECG analysis software. The company also turned a profit in the first quarter.
BONRAYBIO is capitalizing on the growing demand in the fertility sector, offering products such as sperm quality analysis systems, sperm selection devices, and DNA fragmentation analyzers. iXensor has developed its proprietary Pixo image sensing technology and now integrates real-time diagnostics with AI analysis to deliver personalized health management services.
Resource: AI醫療 醫材廠卡位各出奇招
